The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Durability of responses in patients with DLBCL treated with liso-cel: real-world insights
In this video, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, shares insights into the real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting that the durability of responses observed in clinical trials is also seen in the real-world setting. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we’ve known now for some time that liso-cel from clinical trials leads to durable, complete responses, curative outcomes in patients with relapsed/refractory DLBCL. At this meeting, we published a look at real-world outcomes, so looking at the US CIBMTR data. And what we see there is we see the same sort of durability. So in patients in the real world, many of whom would not have actually been trial eligible, so these are sicker patients, maybe more comorbidities, we’re seeing the same kind of durability of outcomes...
So we’ve known now for some time that liso-cel from clinical trials leads to durable, complete responses, curative outcomes in patients with relapsed/refractory DLBCL. At this meeting, we published a look at real-world outcomes, so looking at the US CIBMTR data. And what we see there is we see the same sort of durability. So in patients in the real world, many of whom would not have actually been trial eligible, so these are sicker patients, maybe more comorbidities, we’re seeing the same kind of durability of outcomes. So that’s really encouraging to see, and I think it helps to reinforce the notion that CAR T-cell therapy in relapsed/refractory DLBCL is a curative treatment option.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
